Arcadia Historical Balance Sheet

RKDA Stock

USD 2.76 0.02 0.73%

Trend analysis of Arcadia Biosciences balance sheet accounts such as Total Stockholder Equity of 14.6 M, Property Plant And Equipment Net of 1.1 M, Accounts Payable of 970.9 K or Cash of 6.2 M provides information on Arcadia Biosciences' total assets, liabilities, and equity, which is the actual value of Arcadia Biosciences to its prevalent stockholders. By breaking down trends over time using Arcadia Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Arcadia Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcadia Biosciences is a good buy for the upcoming year.

Arcadia Biosciences Inventory

1.59 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

About Arcadia Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Arcadia Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Arcadia Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arcadia Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arcadia currently owns. An asset can also be divided into two categories, current and non-current.

Arcadia Biosciences Balance Sheet Chart

At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 1.8 M, whereas Short and Long Term Debt Total is forecasted to decline to about 956.6 K.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Temporary Equity Redeemable Noncontrolling Interests

Add Fundamental

Total Assets

Total assets refers to the total amount of Arcadia Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arcadia Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Arcadia Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcadia Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Arcadia Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arcadia Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 1.8 M, whereas Short and Long Term Debt Total is forecasted to decline to about 956.6 K.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	3.3M	2.0M	1.0M	956.7K
Total Assets	43.9M	28.9M	19.7M	35.9M

Short Long Term Debt Total Total Assets

Arcadia Biosciences balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Liab	Other Assets	Long Term Debt
Total Assets		0.56	-0.29	-0.15	0.88	0.29	-0.18	0.03	-0.28	0.51	0.51	0.72	0.11	0.93	-0.19	0.03	0.5	0.21	0.52	0.42	0.43	0.26	0.97	-0.14	0.04	0.49
Short Long Term Debt Total	0.56		0.01	0.17	0.18	-0.19	0.56	0.7	0.52	0.02	0.02	0.56	0.13	0.59	-0.02	-0.51	0.9	-0.41	-0.23	-0.38	0.9	-0.3	0.49	-0.25	0.37	0.94
Other Current Liab	-0.29	0.01		0.75	-0.51	0.23	0.18	0.25	0.22	-0.68	-0.29	-0.2	0.31	-0.26	0.35	-0.27	0.13	0.01	-0.25	-0.3	0.32	0.16	-0.28	0.46	0.43	-0.15
Total Current Liabilities	-0.15	0.17	0.75		-0.34	0.17	0.1	0.07	0.16	-0.28	0.1	0.05	0.6	-0.18	0.37	-0.16	0.05	0.04	-0.17	-0.2	0.31	0.12	-0.2	0.08	0.56	-0.08
Total Stockholder Equity	0.88	0.18	-0.51	-0.34		0.4	-0.47	-0.36	-0.57	0.64	0.67	0.57	0.08	0.81	-0.18	0.27	0.08	0.45	0.76	0.73	-0.01	0.42	0.87	-0.27	-0.13	0.13
Property Plant And Equipment Net	0.29	-0.19	0.23	0.17	0.4		-0.38	-0.37	-0.36	0.01	0.37	0.39	0.47	0.15	0.37	0.1	-0.15	0.86	0.77	0.45	-0.1	0.96	0.22	0.0	0.44	-0.35
Current Deferred Revenue	-0.18	0.56	0.18	0.1	-0.47	-0.38		0.58	0.96	-0.33	-0.26	0.11	-0.12	-0.1	0.31	-0.81	0.6	-0.6	-0.65	-0.89	0.6	-0.55	-0.25	-0.11	0.46	0.57
Net Debt	0.03	0.7	0.25	0.07	-0.36	-0.37	0.58		0.58	-0.44	-0.69	0.05	-0.01	0.1	-0.18	-0.38	0.72	-0.61	-0.55	-0.61	0.7	-0.39	0.02	0.03	0.17	0.73
Retained Earnings	-0.28	0.52	0.22	0.16	-0.57	-0.36	0.96	0.58		-0.33	-0.29	0.06	-0.1	-0.18	0.29	-0.83	0.59	-0.59	-0.69	-0.93	0.61	-0.53	-0.35	-0.03	0.5	0.54
Accounts Payable	0.51	0.02	-0.68	-0.28	0.64	0.01	-0.33	-0.44	-0.33		0.59	0.37	-0.14	0.48	-0.48	0.13	-0.04	0.06	0.34	0.44	-0.11	0.02	0.49	-0.1	-0.26	-0.02
Cash	0.51	0.02	-0.29	0.1	0.67	0.37	-0.26	-0.69	-0.29	0.59		0.5	0.18	0.44	0.28	0.05	-0.1	0.5	0.58	0.47	-0.07	0.3	0.46	-0.28	0.17	-0.08
Non Current Assets Total	0.72	0.56	-0.2	0.05	0.57	0.39	0.11	0.05	0.06	0.37	0.5		0.41	0.51	0.2	-0.1	0.46	0.23	0.29	0.08	0.45	0.35	0.52	-0.26	0.43	0.46
Non Currrent Assets Other	0.11	0.13	0.31	0.6	0.08	0.47	-0.12	-0.01	-0.1	-0.14	0.18	0.41		-0.07	0.42	0.21	-0.11	0.36	0.25	0.09	0.05	0.54	-0.01	-0.41	0.7	-0.07
Cash And Short Term Investments	0.93	0.59	-0.26	-0.18	0.81	0.15	-0.1	0.1	-0.18	0.48	0.44	0.51	-0.07		-0.32	-0.14	0.58	0.06	0.42	0.4	0.5	0.08	0.96	-0.08	-0.05	0.54
Net Receivables	-0.19	-0.02	0.35	0.37	-0.18	0.37	0.31	-0.18	0.29	-0.48	0.28	0.2	0.42	-0.32		-0.22	-0.13	0.36	0.1	-0.27	-0.02	0.26	-0.31	-0.39	0.66	-0.08
Common Stock Shares Outstanding	0.03	-0.51	-0.27	-0.16	0.27	0.1	-0.81	-0.38	-0.83	0.13	0.05	-0.1	0.21	-0.14	-0.22		-0.62	0.44	0.42	0.64	-0.65	0.36	0.06	-0.07	-0.49	-0.42
Non Current Liabilities Total	0.5	0.9	0.13	0.05	0.08	-0.15	0.6	0.72	0.59	-0.04	-0.1	0.46	-0.11	0.58	-0.13	-0.62		-0.41	-0.29	-0.44	0.96	-0.29	0.46	0.13	0.27	0.89
Inventory	0.21	-0.41	0.01	0.04	0.45	0.86	-0.6	-0.61	-0.59	0.06	0.5	0.23	0.36	0.06	0.36	0.44	-0.41		0.88	0.63	-0.38	0.89	0.17	-0.09	0.16	-0.47
Other Current Assets	0.52	-0.23	-0.25	-0.17	0.76	0.77	-0.65	-0.55	-0.69	0.34	0.58	0.29	0.25	0.42	0.1	0.42	-0.29	0.88		0.79	-0.32	0.79	0.53	-0.24	0.02	-0.29
Other Stockholder Equity	0.42	-0.38	-0.3	-0.2	0.73	0.45	-0.89	-0.61	-0.93	0.44	0.47	0.08	0.09	0.4	-0.27	0.64	-0.44	0.63	0.79		-0.47	0.58	0.49	-0.05	-0.4	-0.43
Total Liab	0.43	0.9	0.32	0.31	-0.01	-0.1	0.6	0.7	0.61	-0.11	-0.07	0.45	0.05	0.5	-0.02	-0.65	0.96	-0.38	-0.32	-0.47		-0.24	0.38	0.14	0.41	0.82
Property Plant And Equipment Gross	0.26	-0.3	0.16	0.12	0.42	0.96	-0.55	-0.39	-0.53	0.02	0.3	0.35	0.54	0.08	0.26	0.36	-0.29	0.89	0.79	0.58	-0.24		0.19	-0.01	0.31	-0.43
Total Current Assets	0.97	0.49	-0.28	-0.2	0.87	0.22	-0.25	0.02	-0.35	0.49	0.46	0.52	-0.01	0.96	-0.31	0.06	0.46	0.17	0.53	0.49	0.38	0.19		-0.08	-0.1	0.44
Other Liab	-0.14	-0.25	0.46	0.08	-0.27	0.0	-0.11	0.03	-0.03	-0.1	-0.28	-0.26	-0.41	-0.08	-0.39	-0.07	0.13	-0.09	-0.24	-0.05	0.14	-0.01	-0.08		-0.31	-0.23
Other Assets	0.04	0.37	0.43	0.56	-0.13	0.44	0.46	0.17	0.5	-0.26	0.17	0.43	0.7	-0.05	0.66	-0.49	0.27	0.16	0.02	-0.4	0.41	0.31	-0.1	-0.31		0.17
Long Term Debt	0.49	0.94	-0.15	-0.08	0.13	-0.35	0.57	0.73	0.54	-0.02	-0.08	0.46	-0.07	0.54	-0.08	-0.42	0.89	-0.47	-0.29	-0.43	0.82	-0.43	0.44	-0.23	0.17

Click cells to compare fundamentals

Arcadia Biosciences Account Relationship Matchups

Arcadia Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Other Current Liab	4.5M	3.0M	1.5M	1.3M	1.1M	1.8M
Total Current Liabilities	5.7M	6.3M	5.0M	4.2M	3.6M	4.1M
Total Stockholder Equity	7.7M	27.7M	31.1M	21.0M	12.8M	14.6M
Property Plant And Equipment Net	3.8M	9.4M	5.4M	2.6M	1.2M	1.1M
Current Deferred Revenue	42K	8K	64K	(572K)	(514.8K)	(489.1K)
Net Debt	(6.2M)	(4.7M)	(25.4M)	(18.6M)	(5.5M)	(5.8M)
Retained Earnings	(207.2M)	(211.8M)	(226.5M)	(257.9M)	(271.8M)	(285.4M)
Accounts Payable	492K	726K	1.4M	905K	801K	970.9K
Cash	8.4M	14.0M	28.7M	20.6M	6.5M	6.2M
Non Current Assets Total	4.1M	15.7M	8.5M	3.5M	4.7M	5.5M
Non Currrent Assets Other	372K	5.5M	2.7M	932K	3.5M	2.5M
Cash And Short Term Investments	25.3M	25.7M	28.7M	20.6M	11.6M	11.1M
Net Receivables	602K	1.4M	1.4M	1.2M	514K	767.9K
Common Stock Shares Outstanding	159.1K	249.0K	532.0K	599.4K	1.2M	1.3M
Liabilities And Stockholders Equity	32.6M	47.3M	43.9M	28.9M	19.7M	35.9M
Non Current Liabilities Total	18.5M	12.5M	7.7M	3.8M	3.4M	3.2M
Inventory	1.8M	3.8M	4.4M	2.6M	2.0M	1.6M
Other Current Assets	712K	1.6M	1.8M	1.2M	858K	914.0K
Other Stockholder Equity	214.8M	239.5M	257.5M	278.8M	284.5M	207.1M
Total Liab	24.2M	18.8M	12.7M	8.0M	7.0M	6.7M
Property Plant And Equipment Gross	3.8M	9.4M	5.4M	2.6M	3.7M	2.7M
Total Current Assets	28.4M	31.7M	35.4M	25.4M	15.0M	28.3M
Accumulated Other Comprehensive Income	(4.8M)	1K	0.0	101K	116.2K	122.0K
Other Liab	8.2M	16.9M	5.0M	5.5M	6.3M	8.1M
Other Assets	372K	5.5M	2.7M	1.0	0.9	0.86
Short Term Debt	635K	2.6M	2.1M	2.0M	1.7M	1.6M
Property Plant Equipment	1.1M	2.2M	9.4M	5.4M	6.2M	3.1M
Net Tangible Assets	12.8M	7.7M	26.9M	30.6M	35.2M	37.0M
Common Stock Total Equity	42K	45K	49K	54K	62.1K	51.0K
Retained Earnings Total Equity	(167.3M)	(178.4M)	(207.2M)	(211.8M)	(190.6M)	(200.2M)
Short Term Investments	9.8M	16.9M	11.6M	0.0	5.1M	4.9M
Capital Surpluse	175.2M	191.1M	214.8M	239.5M	275.4M	213.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:

How To Invest In Arcadia

Details

Is Arcadia Stock a good investment?

Details

What is Arcadia Biosciences' Net Worth?

Details

Largest Food, Beverage & Tobacco Companies

View

Largest Consumer Defensive Companies

View

For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.285

Earnings Share

(6.77)

Revenue Per Share

3.802

Quarterly Revenue Growth

(0.04)

Return On Assets

(0.39)

The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcadia Historical Balance Sheet

Arcadia Biosciences Inventory

1.59 Million

About Arcadia Balance Sheet Analysis

Arcadia Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Arcadia Biosciences balance sheet Correlations

Arcadia Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcadia Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.97	Total Assets
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net
Retained Earnings	+ 0.96	Current Deferred Revenue
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total
Long Term Debt	+ 0.94	Short Long Term Debt Total

Other Stockholder Equity	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.89	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Common Stock Shares Outstanding	- 0.81	Current Deferred Revenue
Other Current Assets	- 0.69	Retained Earnings
Cash	- 0.69	Net Debt